AMM européenne pour Scemblix® (asciminib) de Novartis
Novartis Media Release guide - August 2019
Novartis releases long-term Zolgensma data
Novartis' Zolgensma expansion hits FDA roadblock, giving Biogen and Roche a reprieve | Fierce Pharma
Japan's health insurance to cover ¥167 million gene therapy drug - The Japan Times
Zolgensma gene therapy for sma patients: long-term data
Novartis slaps $2M-plus price tag on newly approved gene therapy Zolgensma—and cost watchdogs approve | Fierce Pharma
Novartis used faulty data for world's most expensive drug Zolgensma
Test Achats porte plainte contre un médicament à 2 millions d'euros
FDA Accepts AveXis' BLA for SMA Drug Zolgensma Under Priority Review - Muscular Dystrophy Association
Zolgensma launch 'on track and fully in line' with expectation, says Novartis CEO | Fierce Pharma
Novartis to Open New Trial of Zolgensma for Older SMA Patients
Zolgensma SMA therapy confirms long-term efficacy for up to 7.5 years < Pharma < Article - KBR
ICNApedia - Zolgensma Benefits Observed in Presymptomatic SMA Patients
Four Takeaways from the Zolgensma Pricing Storm
Novartis faces serious delays in registration of Zolgensma in Russia
Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)
R&D report card: Zolgensma-maker Novartis' spending reaches $9.4B in 2019 | S&P Global Market Intelligence
Novartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facility
Novartis says it knew of Zolgensma data problems before U.S. approval - The Japan Times
Novartis allies with Voyager to develop gene therapies in $1.3bn deal
